Clinical Analysis Of 42 Cases With Double Primary Cancers Of Ovarian And Breast

Objective:To explore the clinical features of the conjunction of two types of primary tumors such as breast and ovarian cancer associated with gynecologic malignant tumor.Methods:A retrospective analysis was applied in clinical data referring to 42 cases of ovarian and breast tumors collected in Shanxi Province Tumor Hospital between January of 2000 and December of 2014.Results:42 cases of ovarian cancer in combination with breast cancer were followed up successfully; 36 cases were diagnosed as primary breast cancer and the median survival duration was 247 months, and 1, 2, 5 years survival rates were 83.3%(35/42), 78.6%(33/42)and 66.7%(28/42),respectively; however, the median survival period for those combined with ovarian cancer was 46 months, and 1, 2, 5 year survival rates were 73.8%(31/42),64.3%(27/42)and 14.3%(6/42), respectively; in terms of 4 cases with the first primary ovarian cancer, the survival period was 42-163 months. Moreover, 3 cases were still alive,but the survival time is far less than 60 months in 2 patients; for 4 duplicate primary cancer patients with a family history of breast or ovarian cancer, the 5 year survival rates after the surgery for curing the second primary cancer were4.8%(2/42)respectively; 33 patients with primary breast and ovarian cancers without a family history of malignancy, the 1, 2, 5year survival rates after the surgery for curing the second primary cancer were35.7%(15/42), 21.4%(9/42), and 11.9%(5/42), respectively.Conclusion:For patients with duplicate primary cancers such as ovarian and breast cancer, the staging, extent of differentiation in ovarian cancer are the important factors which have a great influence on the prognosis; compared with primary ovarian cancer happened initially,those with breast cancers have a longer survival period. Furthermore, those having a family or past medical history of ovarian or breast cancer, are taking at higher risk; Therefore,carrying the genetic test on the population with higher risk, and paying more attention to strategies including the screening or follow-up steps, might be beneficial for early discovery, diagnosis as well as treatments, and also avoiding from misdiagnosis and missed diagnosis.